PharmaTutor (October - 2016)
ISSN: 2347 - 7881
(Volume 4, Issue 10)
Received On: 02/05/2016; Accepted On: 07/06/2016; Published On: 01/10/2016
AUTHORS:
Suleman S. Khoja*, Parthkumar H. Chauhan, Maulik N. Patel, Harsha D. Jani
Department of Quality Assurance, Shivam Pharmaceutical Studies and Research Centre, Anand, Gujarat.
*premukhoja@gmail.com
ABSTRACT: Cinnarizine and Dimenhydrinate combination are active contain and approved by CDSCO. The two substances belong to different groups of medicines. Cinnarizine is a part of a group called calcium antagonists. Dimenhydrinate belongs to a group called antihistamines also used in Treatment of vertigo symptoms of various origins. Exhibits anti-emetic and antivertiginous effects through influencing the chemoreceptor trigger zone in the region of the 4th ventricle. Dimenhydrinate thus acts predominantly on the central vestibular system. Due to its calcium antagonistic properties, cinnarizine acts mainly as a vestibular sedative through inhibition of the calcium influx into the vestibular sensory cells. Cinnarizine thus acts predominantly on the peripheral vestibular system. Both cinnarizine and dimenhydrinate are known to be effective in the treatment of vertigo. The combination product is more effective than the individual compounds in the population studied. The product has not been evaluated in motion sickness. Maximum plasma concentrations (Cmax) of cinnarizine and diphenhydramine are reached in humans within 2 - 4 hours. metabolised in the liver. Cinnarizine is mainly eliminated via the faeces (40-60%) and to a lower extent also in urine, mainly in the form of metabolites conjugated with glucuronic acid. The major route of elimination of diphenhydramine is in the urine.
How to cite this article: Khoja SS, Chauhan PH, Patel MN, Jani HD; A Review on chemistry and Pharmacological activity of Cinnarizine and Dimenhydrinate combine dosage form; PharmaTutor; 2016; 4(10); 26-30
[ABSTRACT WITH CITATION] [VIEW AS HTML]
.png)
